Google
KYNB Stock Price & Analysis — Kyntra Bio, Inc. (Healthcare >> Biotechnology)
KYNB FAQ
What is KYNB's P/E ratio?
Kyntra Bio, Inc. (KYNB) currently trades at a P/E ratio of 0.15.
What is KYNB's ROE?
Kyntra Bio, Inc. reports a Return on Equity (ROE) of -373.52%.
What is KYNB's dividend yield?
Kyntra Bio, Inc. offers a dividend yield of 0.00%.
What is KYNB's Quality Score?
Our AI rates KYNB's overall financial quality at 54 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy KYNB?
Our AI Timing Score for KYNB is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does KYNB belong to?
Kyntra Bio, Inc. is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange
KYNB AI Analysis Summary
Our AI summary for KYNB: Kyntra Bio, Inc. (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.15, ROE of -373.52%, a dividend yield of 0.00%. Its financial Quality Score stands at 54/100 — mid-range fundamentals relative to the market. The AI Timing Score is 27/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 6.73
Price
-0.06
(-0.88%)
Day Change
|
|
|---|
KYNB, the overall quality is not quite good ( Quality = 54) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
Acceleration of ROE growth rate is below our criteria.
Negative growth of ROE in the last year.
Acceleration of ROA growth rate is below our criteria.
Current growth of ROA was below our criteria.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are ok , financial health is not good , and ability to make profit is ok , ...
| Quality Factors |
|
67% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | N/A |
| Magic Formula Rank by ROA |
5
GREAT
|
| Magic Formula Rank by ROE |
5
GREAT
|
| Magic Formula Rank by ROIC |
2
GREAT
|
| Price | 6.73 |
| PBV / Sector |
-0.89 / 5.20
|
| Earning Per Share | 40.06 |
| PE / Sector |
0.15 / 19.97
GREAT
|
| PEG or PE/Growth / Sector |
N/A / 1.22
|
| Average 1M Daily Value |
0.08 M
GREAT
|
| Average 1W Daily Value |
0.04 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
68% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-01 08:00:06 |
| Symbol | KYNB |
| Name | KYNTRA BIO, INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 4.05 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 27.49 / 9,903.94 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 350 Bay Street, San Francisco, CA, United States, 94133
Phone: 415 978 1200
Website: https://www.kyntrabio.com
Sector: Healthcare >> Biotechnology
Description: Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was formerly known as FibroGen, Inc. and change its name to Kyntra Bio, Inc. in January 2026. Kyntra Bio, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap